Navigation Links
Frequently used biologic agents might cause acute liver injury
Date:4/29/2013

Bethesda, MD (April 29, 2013) A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. Patients with inflammatory diseases such as Chron's disease or ulcerative colitis often are prescribed tumor necrosis factor-alpha (TNF-α) antagonists, which modify the body's response to infection. Patients with inflammatory arthropathies and selected dermatological diseases are also candidates to receive such compounds.

"TNF-α antagonists are extremely beneficial as therapies for several bowel, joint and skin inflammatory conditions," said Maurizio Bonacini, MD, AGAF, study author and associate clinical professor, University of California, San Francisco. "However, gastroenterologists, internists, rheumatologists and dermatologists all need to be aware of this potential complication and know how to diagnose it. They should conduct tests for autoimmunity early upon diagnosis of abnormalities to determine the proper path of care."

Researchers searched the U.S. Drug-Induced Liver Injury Network database and identified six well-characterized cases of drug-induced liver injury (DILI) in the setting of TNF-α antagonist therapy. Additionally, they reviewed 28 additional cases identified in PubMed. The researchers found acute liver injury in all cases, most frequently autoimmunity and hepatocellular injury, but mixed non-autoimmune patterns and cholestasis (blocked flow of bile from the liver) also occurred. No deaths were attributed to the liver injury; one patient required a liver transplant, which was attributed to pre-existing cirrhosis with superimposed DILI.

Of the TNF-α antagonists, infliximab-associated liver injury has been the best documented, most likely because of its earlier approval and more wide-spread clinical use. Etanercept and adalimumab have also been linked to drug-induced liver injury. So far, there are no published cases found to be linked to natalizumab, golimumab or certolizumab.

The researchers found that liver damage was typically resolved following drug discontinuation, although some patients did benefit from a course of corticosteroids. Importantly, patients treated with an alternative TNF-α after resolution of their liver injury appeared to tolerate the drugs without recurrence.

"If patients who are taking these biologic agents experience symptoms such as abdominal pain, nausea and fatigue, physicians should check liver enzyme levels to determine if the symptoms are a result of these drugs," added Dr. Bonacini.


'/>"/>

Contact: Rachel Steigerwald
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. Frequently prescribed drug used in concerning ways with harmful side effects
2. UC Davis study finds stray-bullet shootings frequently harm women and children
3. Men Biologically Programmed to Steer Clear of Friends Wives
4. Dog Study Raises Prospect of Biological Pacemaker for Humans
5. Medicines quality workshop to address standards for microbiological contamination, bioburden control
6. Dr. Daniel Strader of Dallas Designer Smiles Receives Top Reviews as Local Dallas, TX Dentist for Biological Dentistry
7. Researchers discover biological diversity in triple-negative breast cancer
8. Mayo Clinic-led study unravels biological pathway that controls the leakiness of blood vessels
9. Ordinary heart cells become biological pacemakers with injection of a single gene
10. Cutting-edge approaches to ensuring biologic drug quality focus of forum on bioassays
11. Solving a biological mystery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2020)... ... January 11, 2020 , ... The co-founder and CEO of ... with the annual JP Morgan Healthcare Conference. On Sunday, January 12, Sujuan Ba, ... technology company investors and advisers at the San Francisco office of international law ...
(Date:1/10/2020)... ... January 10, 2020 , ... Sigma Theta Tau International Honor ... of the Year Awards. These awards are regarded as one of the most important ... the AJN Book of the Year competition has recognized Sigma for the last 11 ...
(Date:1/10/2020)... ... January 10, 2020 , ... ... of autoimmune conditions, HMP, a leading healthcare event and education company, today announced ... patient care. , The Autoimmune Learning Network serves as a robust digital hub ...
(Date:1/10/2020)... , ... January 10, 2020 , ... ... in Portland, Oregon, provides a friendly, non-intimidating environment for all women. In search ... Habits to its current and prospective members. , For nearly 30 years, ...
(Date:1/8/2020)... ... 08, 2020 , ... Myant Inc., leaders in Textile Computing™, ... by the Myant Platform at CES 2020, happening January 7-10, in Las ... the Myant Platform will be aware of the worker’s current physical and psychological ...
Breaking Medicine News(10 mins):
(Date:1/7/2020)... (PRWEB) , ... January 07, 2020 , ... ... first calibration-free blood pressure (BP) sensor system for integration in hearables and wearables. ... device and consumer electronics manufacturers for inclusion in their products. Embedded in an ...
(Date:1/7/2020)... ... January 07, 2020 , ... ... Tuesday, Jan. 21, 2020, 11:00 a.m.-12:30 p.m. EST, https://www.fdanews.com/chinanpma , China ... It is the only market with a 20 percent annual growth rate year ...
(Date:1/3/2020)... ... 2020 , ... In Partnership with the Smiles for Everyone Foundation , ... its Burleson, TX office on February 8th. , Dental services provided include same-day procedures ... extractions . For more information, please visit the Monarch Dental website . ...
Breaking Medicine Technology: